FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Fairooz Kabbinavar

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Co-author Network

Publications

TOP 3
Nils Kroeger; P Nagesh Rao; Joseph Riss; Geoffrey A Sonn; Arie S Belldegrun; Frédéric D Birkhäuser; Karim Chamie; Fairooz Kabbinavar; Tobias Klatte; Allan J Pantuck
Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma.
Ferdows Ather; Marlena S Fejzo; Richard S Finn; Habib Hamidi; Christian Head; Fairooz Kabbinavar; Stephen Letrent; Steven G Wong
Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
Tobias Klatte; Nils Kroeger; Joshua E Logan; Edward N Rampersaud; P Nagesh Rao; Joseph Riss; Geoffrey Sonn; Arie S Belldegrun; Frédéric D Birkhäuser; Fairooz Kabbinavar; Allan J Pantuck
Gain of chromosome 8q is associated with metastases and poor survival of patients with clear cell renal cell carcinoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Fairooz Kabbinavar (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Nils Kroeger; P Nagesh Rao; Joseph Riss; Geoffrey A Sonn; Arie S Belldegrun; Frédéric D Birkhäuser; Karim Chamie; Fairooz Kabbinavar; Tobias Klatte; Allan J Pantuck
Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma.
Cancer 2013;119(8):1547-54.
2013: Ferdows Ather; Marlena S Fejzo; Richard S Finn; Habib Hamidi; Christian Head; Fairooz Kabbinavar; Stephen Letrent; Steven G Wong
Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
PloS one 2013;8(2):e56112.
2012: Tobias Klatte; Nils Kroeger; Joshua E Logan; Edward N Rampersaud; P Nagesh Rao; Joseph Riss; Geoffrey Sonn; Arie S Belldegrun; Frédéric D Birkhäuser; Fairooz Kabbinavar; Allan J Pantuck
Gain of chromosome 8q is associated with metastases and poor survival of patients with clear cell renal cell carcinoma.
Cancer 2012;118(23):5777-82.
2012: Fairooz Kabbinavar; Mark F. Kozloff; Amy Sing; Mark A Ashby; Charles E Barr; Patrick J Flynn; Axel Grothey
Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study.
European journal of cancer (Oxford, England : 1990) 2012;48(8):1126-32.
2012: Nils Kroeger; John T Leppert; Arie S Belldegrun; Frédéric D Birkhäuser; Fairooz Kabbinavar; Tobias Klatte; Edward N Rampersaud; P Nagesh Rao; David B Seligson; Nazy Zomorodian; Allan J Pantuck
Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma.
European urology 2012;61(5):888-95.
2012: Nils Kroeger; Edward N Rampersaud; David B Seligson; Nazy Zomorodian; Arie S Belldegrun; Frédéric D Birkhäuser; Fairooz Kabbinavar; Tobias Klatte; Allan J Pantuck
Smoking negatively impacts renal cell carcinoma overall and cancer-specific survival.
Cancer 2012;118(7):1795-802.
2012: Joshua E Logan; Allan J Pantuck; Edward N Rampersaud; Dennis J Slamon; Geoffrey A Sonn; Arie S Belldegrun; Karim Chamie; Fairooz Kabbinavar
Systemic therapy for metastatic renal cell carcinoma: a review and update.
Reviews in urology 2012;14(3-4):65-78.
2011: David S Finley; Gretchen Galliano; Robin A Jeffries; Fairooz Kabbinavar; Clara Magyar; Abdelmonem A Afifi; Arie S Belldegrun; Brandon Castor; Ardavan Sadaat; Jonathan W Said; Brian Shuch; Allan J Pantuck
The chromophobe tumor grading system is the preferred grading scheme for chromophobe renal cell carcinoma.
The Journal of urology 2011;186(6):2168-74.
2011: Fred R Hirsch; Fairooz Kabbinavar; Renato Martins; Frank Richardson; Katherine Richardson; Jason Rusk; Fredrick M Schnell; David W Sternberg; Marileila Varella-Garcia; Bret Wacker; Paul A Bunn; D Ross Camidge; Rafal Dziadziuszko; Tim Eisen; Wilbur A Franklin; D Ross Camidge
A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(26):3567-73.
2011: G R Blumenschein; Y-J Hei; Fairooz Kabbinavar; K Kracht; K Lakshmaiah; H Menon; Tony Shu Kam Mok; Karen Reckamp; L Schwartzberg; R Sikorski; J Stephenson; Y-N Sun; J T Beck
A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(9):2057-67.
2011: Patrick Schöffski; Melanie Smitt; Walter M Stadler; Scott T Tagawa; Xinqun Yang; Min Zhu; Abraham Anderson; Jorge A Garcia; Thierry Gil; Eric Jonasch; Kelly S Oliner; Fairooz Kabbinavar
A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma.
BJU international 2011;108(5):679-86.
2011: Fairooz Kabbinavar; Mark Kozloff
Regarding 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.
Oncology 2011;80(1-2):135-7; author reply 140-1.
2011: Tobias Klatte; Jonathan W Said; David B Seligson; P Nagesh Rao; Michela de Martino; Brian Shuch; Nazy Zomorodian; Fairooz Kabbinavar; Arie S Belldegrun; Allan J Pantuck
Pathological, immunohistochemical and cytogenetic features of papillary renal cell carcinoma with clear cell features.
The Journal of urology 2011;185(1):30-5.
2010: Jeffrey C La Rochelle; Tobias Klatte; Aditi Dastane; Nagesh Rao; David Seligson; Jonathan Said; Brian Shuch; Nazy Zomorodian; Fairooz Kabbinavar; Arie Belldegrun; Allan J Pantuck
Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma.
Cancer 2010;116(20):4696-702.
2010: Sara A Hurvitz; Heather J Allen; Rebecca L Moroose; David Chan; Christopher Hagenstad; Steven H Applebaum; Giribala Patel; Eddie H Hu; Nancy Ryba; Lii-Shin Lin; Hejing Wang; John Glaspy; Dennis J Slamon; Fairooz Kabbinavar
A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01).
Clinical breast cancer 2010;10(4):307-12.
2010: Roy S Herbst; Yan Sun; Wilfried E E Eberhardt; Paul Germonpré; Nagahiro Saijo; Caicun Zhou; Jie Wang; Longyun Li; Fairooz Kabbinavar; Yukito Ichinose; Shukui Qin; Li Zhang; Bonne Biesma; John V Heymach; Peter Langmuir; Sarah J Kennedy; Hiroomi Tada; Bruce E Johnson
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
The lancet oncology 2010;11(7):619-26.
2010: Tobias Klatte; Christine Anterasian; Jonathan W Said; Michela de Martino; Fairooz Kabbinavar; Arie S Belldegrun; Allan J Pantuck
Fuhrman grade provides higher prognostic accuracy than nucleolar grade for papillary renal cell carcinoma.
The Journal of urology 2010;183(6):2143-7.
2010: Brian Shuch; Jonathan Said; Jeffrey C La Rochelle; Ying Zhou; Gang Li; Tobias Klatte; Frederic Pouliot; Fairooz Kabbinavar; Arie S Belldegrun; Allan J Pantuck
Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy.
Cancer 2010;116(3):616-24.
2010: Mark F Kozloff; Jordan Berlin; Patrick J Flynn; Fairooz Kabbinavar; Mark Ashby; Wei Dong; Amy P Sing; Axel Grothey
Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study.
Oncology 2010;78(5-6):329-39.
2009: Michela de Martino; Tobias Klatte; David B Seligson; Jeffrey C La Rochelle; Brian Shuch; Randy Caliliw; Z Li; Fairooz Kabbinavar; Allan J Pantuck; Arie S Belldegrun
CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis.
The Journal of urology 2009;182(2):728-34.
2009: Jeffrey C La Rochelle; Brian Shuch; Stephen B Riggs; Li-Jung Liang; Ardavan Saadat; Fairooz Kabbinavar; Allan J Pantuck; Arie Belldegrun
Functional and oncological outcomes of partial nephrectomy of solitary kidneys.
The Journal of urology 2009;181(5):2037-42; discussion 2043.
2009: Tobias Klatte; Jonathan W Said; Michela de Martino; Jeffrey C La Rochelle; Brian Shuch; Jian Yu Rao; George V Thomas; Fairooz Kabbinavar; Arie S Belldegrun; Allan J Pantuck
Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification.
The Journal of urology 2009;181(4):1558-64; discussion 1563-4.
2009: Tobias Klatte; David B Seligson; Jeffrey C La Rochelle; Brian Shuch; Jonathan W Said; Stephen B Riggs; Nazy Zomorodian; Fairooz Kabbinavar; Allan J Pantuck; Arie S Belldegrun
Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2009;18(3):894-900.
2009: Tobias Klatte; Allan J Pantuck; Jonathan W Said; David B Seligson; Nagesh P Rao; Jeffrey C La Rochelle; Brian Shuch; Amnon Zisman; Fairooz Kabbinavar; Arie S Belldegrun
Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(4):1162-9.
2009: Tobias Klatte; P Nagesh Rao; Michela de Martino; Jeffrey C La Rochelle; Brian Shuch; Nazy Zomorodian; Jonathan Said; Fairooz Kabbinavar; Arie S Belldegrun; Allan J Pantuck
Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(5):746-53.
2009: Fairooz Kabbinavar; Herbert I Hurwitz; Jing Yi; Somnath Sarkar; Oliver Rosen
Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(2):199-205.
2008: Arie S Belldegrun; Tobias Klatte; Brian Shuch; Jeffrey C La Rochelle; David C Miller; Jonathan W Said; Stephen B Riggs; Nazy Zomorodian; Fairooz Kabbinavar; Jean B deKernion; Allan J Pantuck
Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies.
Cancer 2008;113(9):2457-63.
2008: Tobias Klatte; Ken-Ryu Han; Jonathan W Said; Malte Böhm; Ernst Peter Allhoff; Fairooz Kabbinavar; Arie S Belldegrun; Allan J Pantuck
Pathobiology and prognosis of chromophobe renal cell carcinoma.
Urologic oncology 2008;26(6):604-9.
2008: Brian Shuch; Jeffrey C La Rochelle; Tobias Klatte; Stephen B Riggs; Weiqing Liu; Fairooz Kabbinavar; Allan J Pantuck; Arie S Belldegrun
Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival.
Cancer 2008;113(7):1641-8.
2008: Brian Shuch; Jeffrey C La Rochelle; Jon Wu; Tobias Klatte; Stephen B Riggs; Fairooz Kabbinavar; Arie S Belldegrun; Allan J Pantuck
Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance.
Cancer 2008;113(6):1324-31.
2008: Fairooz Kabbinavar; Joel F Wallace; Eric Holmgren; Jing Yi; David Cella; Kathleen J Yost; Herbert I Hurwitz
Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.
The oncologist 2008;13(9):1021-9.
2008: Brian Shuch; Stephen B Riggs; Jeffrey C La Rochelle; Fairooz Kabbinavar; Raffi Avakian; Allan J Pantuck; Jean-Jacques Patard; Arie S Belldegrun
Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm.
BJU international 2008;102(6):692-6.
2008: Tobias Klatte; Jean-Jacques Patard; Michela de Martino; Karim Bensalah; Gregory Verhoest; Alexandre de la Taille; Clément-Claude Abbou; Ernst Peter Allhoff; Giuseppe Carrieri; Stephen B Riggs; Fairooz Kabbinavar; Arie S Belldegrun; Allan J Pantuck
Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas.
The Journal of urology 2008;179(5):1719-26.
2008: Carolyn D Britten; Fairooz Kabbinavar; J Randolph Hecht; Carlo L Bello; Jim Li; Charles Baum; Dennis J Slamon
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.
Cancer chemotherapy and pharmacology 2008;61(3):515-24.
2008: Fairooz Kabbinavar; Cornelia Irl; Alfredo Zurlo; Herbert I Hurwitz
Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk.
Oncology 2008;75(3-4):215-23.
2008: Rishi Sawhney; Fairooz Kabbinavar
Angiogenesis and angiogenic inhibitors in renal cell carcinoma.
Current urology reports 2008;9(1):26-33.
2008: Tobias Klatte; David Seligson; John T Leppert; Stephen B Riggs; Hong Yu; Nazy Zomorodian; Fairooz Kabbinavar; Robert M Strieter; Arie S Belldegrun; Allan J Pantuck
The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma.
The Journal of urology 2008;179(1):61-6.
2007: Tobias Klatte; David Seligson; Stephen B Riggs; John T Leppert; Maria K Berkman; Mark D Kleid; Hong Yu; Fairooz Kabbinavar; Allan J Pantuck; Arie S Belldegrun
Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(24):7388-93.
2007: Ronald M Bukowski; Fairooz Kabbinavar; Robert A Figlin; Keith Flaherty; Sandy Srinivas; Ulka Nitin Vaishampayan; Harry A Drabkin; Janice Dutcher; Sarah Ryba; Qi Xia; Frank Scappaticci; David McDermott
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(29):4536-41.
2007: Eric J Small; Joseph A Fontana; Nizar M Tannir; Robert S DiPaola; George Wilding; Mark Rubin; Renee Bailey Iacona; Fairooz Kabbinavar
A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer.
BJU international 2007;100(4):765-9.
2007: Tobias Klatte; Allan J Pantuck; Stephen B Riggs; Mark D Kleid; Brian Shuch; Nazy Zomorodian; Fairooz Kabbinavar; Arie S Belldegrun
Prognostic factors for renal cell carcinoma with tumor thrombus extension.
The Journal of urology 2007;178(4 Pt 1):1189-95; discussion 1195.
2007: Frank Scappaticci; Jamey R Skillings; Scott N Holden; Hans-Peter Gerber; Kathy D Miller; Fairooz Kabbinavar; Emily Bergsland; James Ngai; Eric Holmgren; Jiuzhou Wang; Herbert I Hurwitz
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Journal of the National Cancer Institute 2007;99(16):1232-9.
2007: Tobias Klatte; Jean-Jacques Patard; Rakhee H Goel; Mark D Kleid; Francois Guille; Bernard Lobel; Claude C Abbou; Alexandre de la Taille; Jacques Tostain; Luca Cindolo; Vincenzo Altieri; Vincenzo Ficarra; Walter Artibani; Tommaso Prayer-Galetti; Ernst Peter Allhoff; Luigi Schips; Richard Zigeuner; Robert A Figlin; Fairooz Kabbinavar; Allan J Pantuck; Arie S Belldegrun; John S Lam
Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience.
The Journal of urology 2007;178(1):35-40; discussion 40.
2007: Tobias Klatte; Heiko Wunderlich; Jean-Jacques Patard; Mark D Kleid; John S Lam; Kerstin Junker; Jörg Schubert; Malte Böhm; Ernst Peter Allhoff; Fairooz Kabbinavar; Maxime Crepel; Luca Cindolo; Alexandre de la Taille; Jacques Tostain; Arnaud Mejean; Michel Soulie; Laurent Bellec; Jean Christophe Bernhard; Jean-Marie Ferriere; Christian Pfister; Baptiste Albouy; Marc Colombel; Amnon Zisman; Arie S Belldegrun; Allan J Pantuck
Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience.
BJU international 2007;100(1):21-5.
2007: Tobias Klatte; Jean-Jacques Patard; Heiko Wunderlich; Rakhee H Goel; John S Lam; Kerstin Junker; Jörg Schubert; Malte Böhm; Ernst Peter Allhoff; Fairooz Kabbinavar; Maxime Crepel; Luca Cindolo; Alexandre de la Taille; Jacques Tostain; Arnaud Mejean; Michel Soulie; Laurent Bellec; Jean Christophe Bernhard; Jean-Marie Ferriere; Christian Pfister; Baptiste Albouy; Marc Colombel; Amnon Zisman; Arie S Belldegrun; Allan J Pantuck
Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval.
The Journal of urology 2007;177(6):2081-6; discussion 2086-7.
2006: Christopher J Sweeney; Bruce J Roth; Fairooz Kabbinavar; David J Vaughn; Michael Arning; Rafael E Curiel; Coleman K Obasaju; Yanping Wang; Steven J Nicol; Donald S Kaufman
Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(21):3451-7.
2006: Adrian M Jubb; Herbert I Hurwitz; Wei Bai; Eric Holmgren; Patti Tobin; A Steven Guerrero; Fairooz Kabbinavar; Scott N Holden; William F Novotny; Gretchen D Frantz; Kenneth J Hillan; Hartmut Koeppen
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(2):217-27.
2005: Frank Scappaticci; Louis Fehrenbacher; Thomas Cartwright; John D Hainsworth; William Heim; Jordan Berlin; Fairooz Kabbinavar; William F Novotny; Somnath Sarkar; Herbert I Hurwitz
Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.
Journal of surgical oncology 2005;91(3):173-80.
2005: William L Ince; Adrian M Jubb; Scott N Holden; Eric Holmgren; Patti Tobin; Meera Sridhar; Herbert I Hurwitz; Fairooz Kabbinavar; William F Novotny; Kenneth J Hillan; Hartmut Koeppen
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.
Journal of the National Cancer Institute 2005;97(13):981-9.
2005: Fairooz Kabbinavar; Julie Hambleton; Robert D Mass; Herbert I Hurwitz; Emily Bergsland; Somnath Sarkar
Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(16):3706-12.
2005: Fairooz Kabbinavar; Joseph Schulz; Michael McCleod; Taral Patel; John T Hamm; J Randolph Hecht; Robert Mass; Brent Perrou; Betty Nelson; William F Novotny
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(16):3697-705.
2005: Herbert I Hurwitz; Louis Fehrenbacher; John D Hainsworth; William Heim; Jordan Berlin; Eric Holmgren; Julie Hambleton; William F Novotny; Fairooz Kabbinavar
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(15):3502-8.
2005: Matthew R Smith; Fairooz Kabbinavar; Fred Saad; Arif Hussain; Marc Gittelman; David L Bilhartz; Chris Wynne; Robin Murray; Norman R Zinner; Claude Schulman; Ronald Linnartz; Ming Zheng; Carsten Goessl; Yong-Jiang Hei; Eric J Small; Richard Cook; Celestia S Higano
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(13):2918-25.
2005: Herbert I Hurwitz; Fairooz Kabbinavar
Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.
Oncology 2005;69 Suppl 3():17-24.
2004: Christos Emmanouilides; Mark D Pegram; R Robinson; R Hecht; Fairooz Kabbinavar; William H Isacoff
Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer.
Techniques in coloproctology 2004;8 Suppl 1():s50-2.
2004: Fairooz Kabbinavar; Lee M Ellis
Can inhibition of angiogenic pathways increase the efficacy of intravenous 5-fluorouracil-based regimens?
Clinical colorectal cancer 2004;4 Suppl 2():S69-73.
2004: Herbert I Hurwitz; Louis Fehrenbacher; William F Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
The New England journal of medicine 2004;350(23):2335-42.
2004: David H Johnson; Louis Fehrenbacher; William F Novotny; Roy S Herbst; John Nemunaitis; David M Jablons; Corey J Langer; Russell F DeVore; Jacques Gaudreault; Lisa A Damico; Eric Holmgren; Fairooz Kabbinavar
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(11):2184-91.
2004: David J Vaughn; Archie W Brown; W Graydon Harker; Sang Huh; Lance Miller; David Rinaldi; Fairooz Kabbinavar
Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma.
Cancer 2004;100(4):746-50.
2003: Timothy F Cloughesy; Emese Filka; John Kuhn; Gillian Nelson; Fairooz Kabbinavar; Henry Friedman; Langdon L Miller; Gary L Elfring
Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
Cancer 2003;97(9 Suppl):2381-6.
2003: M Jane Arboleda; John F Lyons; Fairooz Kabbinavar; Mark R Bray; Bryan E Snow; Raul Ayala; Mordechai Danino; Beth Y Karlan; Dennis J Slamon
Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells.
Cancer research 2003;63(1):196-206.
2003: Fairooz Kabbinavar; Herbert I Hurwitz; Louis Fehrenbacher; Neal J Meropol; William F Novotny; Grazyna Lieberman; Susan Griffing; Emily Bergsland
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(1):60-5.
2002: Timothy F Cloughesy; Emese Filka; Gillian Nelson; Fairooz Kabbinavar; Henry Friedman; Langdon L Miller; Gary L Elfring
Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
American journal of clinical oncology 2002;25(2):204-8.
2000: LM Strawn; Fairooz Kabbinavar; D P Schwartz; E Mann; Laura K Shawver; Dennis J Slamon; Julie M Cherrington
Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(7):2931-40.
1999: Zuleima Aguilar; Robert W Akita; Richard S Finn; B L Ramos; Mark D Pegram; Fairooz Kabbinavar; Richard J Pietras; Paul I Pisacane; Mark X Sliwkowski; Dennis J Slamon
Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells.
Oncogene 1999;18(44):6050-62.
1999: Mark D Pegram; S Hsu; G Lewis; Richard J Pietras; Malgorzata Beryt; Mark X Sliwkowski; D Coombs; D Baly; Fairooz Kabbinavar; Dennis J Slamon
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Oncogene 1999;18(13):2241-51.
1999: Timothy F Cloughesy; KL Black; Yves Gobin; Keyvan Farahani; G Nelson; Pablo Villablanca; Fairooz Kabbinavar; F Viñeula; C H Wortel
Intra-arterial Cereport (RMP-7) and carboplatin: a dose escalation study for recurrent malignant gliomas.
Neurosurgery 1999;44(2):270-8; discussion 278-9.
1997: Timothy F Cloughesy; Yves Gobin; KL Black; Fernando Viñuela; F Taft; B Kadkhoda; Fairooz Kabbinavar
Intra-arterial carboplatin chemotherapy for brain tumors: a dose escalation study based on cerebral blood flow.
Journal of neuro-oncology 1997;35(2):121-31.